Neuromedin S (NMS) is a neuropeptide identified as another endogenous ligand for two orphan G protein-coupled receptors, FM-3/GPR66 and FM-4/TGR-1, which have also been identified as types 1 and 2 receptors for neuromedin U structurally related to NMS. Although expression of NMS mRNA is found mainly in the brain, spleen, and testis, the distribution of its peptide has not yet been investigated....

BACKGROUND Neuroleptic malignant syndrome (NMS) is a rare side-effect of neuroleptic medication. Most NMS reports have been on adults, and the incidence in children and adolescents is unknown. OBJECTIVE This report reviews cases of NMS to highlight possible risk factors for the development of NMS in adolescents. METHOD Four cases of probable NMS in adolescents diagnosed in the Western Cape ...

1 The concept of Pattern Mining has obtained significant focus in Telecommunications Network Management System (NMS). A big volume of literature has been dedicated to this field and valuable progress was also observed. Both sequential and structured pattern mining techniques were observed to be considered in NMS. In particular NMS logs (Performance and Alarm) pose several interesting issues for...

The accelerating production and use of engineered nanomaterials (NMs) raises questions about the safety of this new technology. To avoid the possible hazards associated with NMs requires proper regulation. How should toxicity testing be addressed and can standard tests for assessment of safety of chemicals be applied to NMs? What are the major limitations of NM safety testing and is the current...

Parkinson's disease (PD) management has traditionally focused largely on motor symptoms. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPi) are effective treatments for motor symptoms. Nonmotor symptoms (NMSs) may also profoundly affect the quality of life. The purpose of this pilot study was to evaluate NMS changes pre- and post-DBS utilizing two r...

Neonatal maternal separation (NMS) is a form of stress that disrupts respiratory control development. Awake adult male rats previously subjected to NMS show a ventilatory response to hypercapnia (HCVR; Fi(CO(2)) = 0.05) 47% lower than controls; however, the underlying mechanisms are unknown. To address this issue, we first tested the hypothesis that carotid bodies contribute to NMS-related atte...

Neuroleptic malignant syndrome (NMS; ICD-10 code: G21.0) is a rare, although potentially life-threatening adverse reaction to antipsychotic drugs and other dopamine-modulating agents. Symptoms of NMS include: severe muscle rigidity, fever, autonomic instability, mental status changes and laboratory abnormallities (elevated serum levels of creatinine kinase, aldolase, transaminases, lactic acid ...

A novel 36-amino acid neuropeptide, neuromedin S (NMS), has recently been identified in rat brain and has been shown to be an endogenous ligand for two orphan G protein-coupled receptors, FM-3/GPR66 and FM-4/TGR-1. These receptors have been identified as neuromedin U (NMU) receptor type 1 and type 2, respectively. In this study, the physiological role of the novel peptide, NMS, on feeding regul...

Neuroleptic malignant syndrome (NMS) is a life-threatening adverse reaction to antipsychotic drugs. Although there is no specific examination able to diagnose NMS, serum creatine kinase (CK) elevation has been reported in over 90% of NMS patients. In this report, we describe a patient who developed NMS but had normal CK levels. The patient presented with hyperthermia of over 38°C, severe muscle...

Malignant tumor (cancer) remains as one of the deadliest diseases throughout the world, despite its overall mortality drops. Nanomaterials (NMs) have been widely studied as diagnostic and/or therapeutic agents for tumors. A feature of NMs, compared to small molecules, is that NMs can be concentrated passively in tumors through enhanced permeability and retention (EPR) effect. In the meantime, N...